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ABSTRACT
THE EFFECT OF FLUVASTATIN ON MAST CELL FUNCTION: GENOTYPE
DEPENDENCE.

By
Elizabeth Motunrayo Kolawole

A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2014
Director: John J. Ryan, Professor, Department of Biology

Fluvastatin, the HMG-CoA reductase inhibitor known for its role in the
treatment of hypercholesterolemia and cardiovascular disease, has more
recently been shown to play a role in the immune response. Given the critical
role that mast cells play in allergy and inflammatory diseases such as asthma,
which effects one third of America’s population, we assessed the effect of

	
  
fluvastatin on mast cell and basophils function. We demonstrate that
fluvastatin downregulated IgE-mediated cytokine production. Additionally, in vivo
studies

showed

that

fluvastatin

suppressed

IgE-mediated

anaphylaxis.

Interestingly, the effects of fluvastatin showed dependence on genetic
background, as C57BL/6 mast cells were sensitive, while 129/Sv mast cells were
resistant to fluvastatin. Characterizing the role of fluvastatin on mast cells may
prove to be therapeutically important.

	
  

Part I
The effect of fluvastatin on mast cell function:
genotype dependence

	
  

CHAPTER 1 - INTRODUCTION:
Immunology- a brief war and peace
From a distance the human body looks serene, but on closer inspection a
battle ensues. Life is an epic fight. The ability to thwart the onslaught of diseasecausing agents is a constant struggle that all living organisms face. With
increasing complexity of the organism, more elaborate plans of defense are
devised and implicated. We call this defense mechanism the immune system.
The immune system, beautiful in its complexity, at its best goes unnoticed. Only
when an invader breaches our front lines or our defenses turn on us do we see
any evidence of its existence. It is in this defective state that we realize how truly
intricate and multifaceted our immune system is. Thus, we try to restore the
balance, giving rise to the field of immunology.
Throughout history, immunology and the treatment of disease has gone by
many names and taken a plethora of forms and iterations. Known as shamanism
or divination, healing by supernatural means in ancient times or physician,
civilizations have always revered those who possess such capabilities and
sometimes feared them. The Smith and Ebers papyrus dating back to 1500 B.C.
are ancient Egyptian documents, providing remedies for various illnesses from
the use of bark, which contains acetylsalicylic acid, an active ingredient of
aspirin, to the treatment of burns and brain injuries (1). While the Egyptians of
1500 B.C. did not know about microorganisms, they knew to treat with copper
salts and honey to prevent infection (2) and had healers specializing in different
organs.
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In 430 B.C Thucydides writes of, “the plaque of Athens” (typhoid fever)
and how those who had recovered were then able to treat the sick as they had
become unsusceptible. Thucydides might well have been influenced by the great
philosophers and historians of his time, such as Hippocrates, Socrates and
Galen, who theorized that the body was composed of 4 vital fluids called humors
- blood, phlegm, yellow bile and black bile - and that an imbalance between these
4 led to disease. Aristotle was the first to study anatomy in animals, and
Herophilus the first to conduct human dissections. Hippocrates believed in
starvation for fevers and feeding for colds. Galen however, believed in
bloodletting, often using leaches to resolve the humoral imbalance.
Humoralism has been a prevailing theory throughout history, though it
has taken many forms, with those in India and China having similar ideas. Indian
traditions believed in three humors. Kapna or phlegy was composed of earth and
water. Pitta, or bile, being fire and water. Vata was described as being wind or
air. Tibetans believed that a blockage of these fluids led to disease and so taking
the pulse was important in the identification of such blockages. In the 9th century
in the Persian Empire Al-Razi wrote a book of medicine, where he documented
and was able to identify allergic reactions, and reasoned that fever was the body
fighting disease. Following him, Ibn-Sina’s correctly described blood circulation
and recognizied that quarantine was required to prevent the spread of infectious
disease.
Variolation came before vaccination and dates back to 10th century China
where powdered lesions from those with smallpox would be exposed to the
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healthy. The numerous delivery methods and vast discrepancies between
quantities being used as treatments occasionally resulted in death and
disfigurement and therefore were not widely accepted.
From the time of Thucydides, different cultures had recognized that some
diseases

were

contagious.

Many

believed

that

these

diseases

arose

spontaneously, an idea that persisted from the time of Aristotle. However, during
the renaissance the scientific method of observing, conducting experiments and
reaching conclusions moved at a faster pace. In the 18th century James Lind
proved that citrus fruits cured scurvy. Subsequently, the English physician
Edward Jenner intentionally used cowpox and a vaccine for small pox and the
etiology of disease began to be understood.
It was not until the end of the 19th century that the French chemist Louis
Pasteur quashed the concept of spontaneous generation. Pasteur’s “Germ
Theory” (1860) states that microorganisms cause disease and that they are ever
present. Pasteur also proposed that microorganisms needed to be prevented
from entering the body during surgeries, which lead to Joseph Lister developing
the antiseptic surgical method. Pasteur also showed that it was microorganisms
that are responsible for milk souring and that fermentation is a result of
microorganism growth (1858-59). This, along with his development of early
vaccines for anthrax, cholera, and tuberculosis earned him the title of the “father”
of immunology. Whilst Pasteur is known for early vaccines to these diseases, it
was Robert Koch who identified the specific bacteria Bacillus anthracis, Vibrio
Cholera and Mycobacterium tubercerculosis being causative for Anthrax, cholera
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and tuberculosis respectively, giving rise to bacteriology. Furthermore, “Koch’s
postulates” brought about a method of determining if a given microorganism was
the causative agent for a particular disease. This vast body of work earned Koch
the Nobel Prize in 1905.
The 20th century saw the dawn of modern immunology, with many brilliant
scientists in addition to Pasteur and Koch. Behring’s anti-diphtheric serum
showed immunity can be transferred, earning him the first Nobel Prize in
medicine in 1901. Mechnikov and Ehrlich were awarded for recognizing antibody
generation, and Ehrlich for many more wonders, such as chemotherapy and
identification of mast cells. He is accredited for being “the father of histology” and
conceived the idea of the immune system being able to direct responses against
“itself”. Metchnikoff is esteemed for identifying phagocytosis. These great minds,
all of which received the Noble Prize in Medicine inside a decade of each other,
along with many more paved for way for immunology, unveiling the immune
system and its complexities.
This period of history marked the beginning of a new era, a time when
scientists would not simply react to some terrible outbreak of disease, but
actually begin to unravel the inner working of interactions between host and
microorganism. This identification of cause and effect allowed remedies and
preventative measures to be outlined. Thus, modern immunology was born.
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Immunity –A tale of two theories
The end of the 19th century and 20th century saw a debate between two
conflicting theories: the long standing, ever-evolving theory of humoralism, and
the immunological wonders that opposed it. Modern humoralism was initiated by
Ehrlich’s group at the Institute of Infectious Disease in Berlin, with Metchnikoff’s
group in opposition at the Pasteur Institute in Paris. Humoralism was the
prevailing theory of the early 1900’s, predominantly led by Ehrlich’s proposition
that antibodies are responsible for immunity. This inspired subsequent
generations, supported by the likes of Von Behring’s transferable immunity
(1890), Roux’s passive immunity (1891), and Bordet’s complement and antibody
activity in bacteriolysis (1894) to name but a few. Metchnikoff’s discovery of
Phagocytic cells (1884) inspired the cellularist theory. Phenomenons such as
Koch’s uncovering delayed type hypersensitivity (1883) and Medawar’s
hypothesis of allograft rejection (1944) suggested that antibodies were not the
definitive immune component, fostering the spread of skepticism regarding the
all-encompassing humoral theory and making way for the concept that
phagocytic cells were the prominent component of immunity.
The case for Humoralism was strengthened by the immunochemistry work
of Heidelberger who demonstrated the precise method for the determination of
antibodies, antigen and complement on a weight basis, giving rise to
Radioimmunoassays (RIA) and Enzyme Linked Immunosorbent Assays (ELISA).
Furthermore, Heidelberger showed that polysaccharides in addition to proteins
can act as antigens. Heidelberger in conjunction with Kabat (1953) paved the
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way for the understanding of the immunoglobulin molecule, which was elucidated
by Porter and Edelman (1959) firmly solidifying the humoral theory. Definitive
proof of the Celluarist Theory came from the work of Landsteiner and Chase
(1942). They showed that cells transferred from a guinea pig immunized against
Mycobacterium tuberculosis to naïve mice and then injected with antigen,
underwent an immune response, not seen in mice when the serum fraction was
transferred. This showed irrefutable proof that antibodies alone did not
orchestrate the immune response and that leucocytes play a role, as later shown
by Gowen (1962).

Ehrlich v Metchnikoff
Ehrlich’s camp and Metchnikoff’s camp both sought to prove the other
wrong with many scientists believing that it was one theory or the other. But
ultimately, both were correct.
Innate immunity
The innate immune system, pioneered by Metchnikoff’s phagocytic cells,
is the first response to infection. It begins with a physical barrier to the external
environment, encompassing the skin and mucosal surfaces. The cellular fraction
is composed of circulating cells (basophils, monocytes, eosinophils and
neutrophils) and resident cells (mast cells, newly recruited monocytes and
macrophages), which migrate to these physical barriers. These cells are
activated via receptors such as toll-like receptors (TLR) or immunoglobulin
receptors (FcR), and secrete chemokines and cytokines in addition to lipid
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mediators, which recruit additional immune cells. The humoral fraction of innate
immunity includes activation of the complement cascade.
Adaptive immunity
The adaptive immune system, pioneered by Ehrlich, can be expanded
beyond antibodies. Antigen presenting cells (APC) described as “professional” or
“non-professional” process and then present antigen fragments to T cells using
Major Histocompatibility Complex (MHC) proteins. T cells assist in B cell
maturation and differentiation into memory B cells and plasma cells. B cells can
undergo isotype switching and somatic hypermutation, producing different
antibodies such as IgA, IgD, IgE, and IgG, which bind antigen. Antibodies have
many functions, some of which are to neutralize toxins, target infectious
organisms, activate complement and promote activation of mast cells,
neutrophils, and macrophages.

Mast cells: Importance to innate immunity
Mast cells are classically known for their integral role in IgE-dependent
allergic disease such as anaphylaxis and asthma, with anaphylaxis effecting 2%
of the American population (3).The prevalence of asthma alone has reached
epidemic proportions in westernized countries with an estimated 39.1 million
Americans being diagnosed in 2011 and an estimated 6,278 fatalities (4).
In recent years, it has been shown that the mast cell’s role is multifaceted
and extends beyond allergic disease, having a key role in inflammatory
conditions such as multiple sclerosis	
   (5, 6), rheumatoid arthritis (7), and
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atherosclerosis (8). In addition, a mast cell role is not limited to the harmful
immune responses, as they participate in host defense against viral (9) and
bacterial pathogens (10), as well as immunosuppressive capabilities in
connection with allograph tolerance (11) and contact dermatitis (12) (13).
Furthermore, mast cells have also been documented at tumor sites and
associated with tumor progression (14),(15). The role in tumor biology appears to
be linked to promoting angiogenesis, tissue remodeling, and tissue repair (16).
These vast amounts of data demonstrate the plethora of complex roles mast
cells have. Thus elucidating the mechanisms mast cells employ are of great
importance.
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Figure 1
The inflammatory mechanism in allergic inflammation.
Antigen is engulfed by antigen presenting cells (APC). It is then processed by
and presented to CD4+ T helper (Th) cells. Th1 production of IFN-γ down
regulates the Th2 response, while Th2 production of IL-4 down suppresses Th1
responses. IL-4 is also responsible for class switching of B cell antibody
production to IgE. B cells produce IgE that binds to FcεRI receptors present in
high abundance on mast cells and basophils. Additional Th2 cytokines such as
IL-3 and IL-5 stimulate eosinophils and basophils to become active. IgE bound to
FcεRI is cross-linked by antigen and become activated to release preformed
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chemical mediators such as histamine, lipid mediators, such as leucoktriene C4
(LTC4), platelet-activating factor (PAF) and de novo cytokines, chemokines and
growth factors. These mediators can yield symptoms from mild rhinitis to
anaphylactic shock, by inducing vasodilation, contraction of the bronchial smooth
muscle and increased mucus secretion in the lungs.
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A mast cell rises
Mast cells derive from distinct hematopoietic stem cell (HSC) precursors.
Human mast cells arise from pluripotent CD34+ progenitor cells (17), whereas
the mouse mast cell progenitors (MCP) are derived from Thy-1lo c-kit

high

and

express c-kit, FcεRI, ST2 and integrin β (18-20). Whilst development begins in
the bone marrow, maturation is completed after immature mast cells migrate
through the peripheral blood to vascularized tissues. Interleukin (IL) 3 is
important for the development of most hematopoietic lineages, including mast
cells.

Stem cell factor (SCF) is also important for early development and

proliferation of hematopoietic cells (21). However, while other hematopoietic
lineages downregulate the SCF receptor c-Kit while immature, mast cells
maintain expression. Furthermore, SCF is imperative to mast cell proliferation,
survival and activation (22), making the combination of IL-3 and SCF receptors
distinct markers of mature mast cells.
Mast cells can be found throughout the body with the exception of the
blood. Being largely known for their role in innate immunity, they are strategically
placed at the interface to the external world and are found in high numbers in the
lungs, skin and mucosal surfaces (20, 23, 24). In connective and mucosal
tissues, mast cell maturation is the product of their microenvironment. Mast cells
can be activated by an array of different stimuli ranging from immunoglobulin,
microbial products such as lipopolysaccharide (LPS) and various cytokines and
chemokines (20, 21). Their subsequent activation, resulting in the release of
preformed and newly synthesized mediators has a substantial impact on their
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microenvironment. The mast cell response can be broadly divided into a proinflammatory response leading to cellular migration and infiltration and the antiinflammatory response, which can result in venom degradation, T-reg migration
and immunosuppression (Figures 2 and 3).
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Figure 2
Mast cells: Two arms of activation.
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Mast cells can be activated by an array of different stimuli, resulting in proinflammatory or anti-inflammatory responses mediated by preformed or newly
synthesized factors.
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Figure 3
Activation via the FcεRI receptor.
Mast cells are most commonly activated by the high affinity FcεRI receptor.
Upon FcεRI aggregation with antigen and IgE, mast cells are activated. Initial
stimulation leads to the release of preformed chemical mediators, followed by
synthesis of newly-formed chemical mediators such as chemokines and
cytokines. These factors result in a myriad of immune responses that act on the
surrounding microenvironment.
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Statins
Statins are a class of drugs widely used in the treatment of
hypercholesterolemia and cardiovascular disease, cardiovascular disease being
the leading cause of deaths in the western world (25). Statins act by
competitively inhibiting the 3-hydroxy -3-methyglutaryl coenzyme A (HMG-CoA)
reductase enzyme and subsequently reduces intermediates, downstream of
HMG-CoA, resulting in reduced cholesterol (25). Statin chemical structure plays
a role in hydrophobicity and consequently, their ability to be absorbed and
metabolized, distributed and excreted (26). Recently, it has become apparent
that

statins

exhibit

anti-oxidant,

anti-atherosclerotic,

anti-thrombotic

and

immunomodulatory functions in addition to lipid lowering {Liao:2005eo}(27). In
the rabbit atherosclerosis model, atorvastatin significantly reduced neointimal
inflammation and macrophage infiltration (28). Lovastatin has been shown to
decrease surface expression of CD11b on monocytes and CD11b-dependent
adhesiveness to fixed endothelium (29).
These immunomodulations have been attributed to the fact that the
cholesterol biosynthesis pathway also generates a series of vital isoprenoids
involved in modifying cell signaling proteins. In particular, the geranylated and
farnesylated proteins, which include the small GTPase family such as Ras, Rac
and Rho, are responsible for controlling multiple cell signaling pathways. It is
therefore not surprising that statins affect more that just cholesterol formation and
exert additional pleiotropic effects.

	
  

It has been shown that statins can suppress TNF and IL-1β production
16	
  

	
  
from macrophages (30) and that statins can suppress mast cell degranulation in
rat cell lines (26). In spite of these revelations, the mechanism has yet to be
elucidated. Thus, outlining the mechanisms whereby statins alter mast cell
responses may prove to be crucial in terms of alternative therapies for allergic
disease.
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Figure 4
The cholesterol biosynthesis pathway.
The cholesterol biosynthesis pathaway or mevalonic acid pathway.
The mevalonic acid pathway is required for the biosynthesis of a range of
important molecules, namely cholesterol and the generation of prenylated
proteins.

Statins

are

competitive

inhibitors

intermediates in the mevalonate pathway.
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CHAPTER 2 – METHODS & MATERIALS:
Animals
C57BL/6, 129/SvImJ (henceforth referred to as 129/sv) , Balb/c, A/HeJ and
C3H/HeJ mice were purchased from The Jackson Laboratory (Bar Harbor, ME)
and used at a minimum of 12 weeks old, with approval from the Virginia
Commonwealth University institutional animal care and use committee (IACUC).
Cells
Mouse bone marrow-derived mast cells (BMMCs) were extracted from mice
femurs and cultured for 21 days in complete RPMI 1640 medium (Invitrogen Life
Technologies, Carlsbad, CA) containing 10% FBS, 2 mM l-glutamine, 100 U/ml
penicillin, 100 µg/ml streptomycin, 1 mM sodium pyruvate, and 1 mM HEPES
((cRPMI); all materials from Biofluids, Rockville, MD), supplemented with IL-3–
containing supernatant from WEHI-3 cells and stem cell factor (SCF)-containing
supernatant from BHK-MKL cells. The final concentration of IL-3 and SCF was
adjusted to 1 or 10 ng/ml, respectively as measured by ELISA. Mouse bone
marrow-derived

basophils

were

cultured

in

cRPMI

supplemented

with

recombinant IL-3 at 20ng/ml (Biolegend, San Diego, CA), for 7-10 days, then
sorted by flow cytometry selecting for CD49b-positive cells (Biolegend).
Human mast cell culture
All protocols involving human tissues were approved by the human studies
Internal Review Board at the University of South Carolina. Surgical skin samples
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were obtained from the Cooperative Human Tissue Network of the National
Cancer Institute or from the National Disease Research Interchange. Skin MCs
were prepared and cultured as described previously (31) and were used after 6–
10 week, at which time purity was essentially 100% mast cells, as determined by
staining with toluidine blue.
IgE-mediated activation
Human MC or BMMC were sensitized overnight with DNP-specific mouse IgE
(1.0µg/ml for human MC; 0.5 µg/ml for BMMC), washed to remove excess
unbound IgE and stimulated with DNP-HSA (Ag; 30 or 20 ng/ml for human MC or
mouse BMMC, respectively). Ionomycin (1µM) was used as positive control.
Passive Systemic Anaphylaxis
Mice were administered 200µl of PBS containing 1mg fluvastatin or equivalent
dilution of DMSO via intraperitoneal injection, followed by 200µl of PBS
containing 50ng of mouse anti-IgE. The following day, DNP-HSA 50µg/ml was
administered via intraperitoneal injection. In some experiments, 5mg of histamine
was injected in place of antigen. The core body temperature of each mouse was
measured using a rectal microprobe (Physitemp Instruments) at regular intervals.
Mice were euthanized using with CO2 asphyxiation, and blood was collected by
cardiac puncture to analyze plasma.
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Cytokines and reagents
All cytokines, including murine IL-3, SCF, were purchased from Biolegend.
Mouse IgE was generously provided by Dr. Daniel Conrad (VCU). Purified
mouse IgE (clone C38-2, κ isotype) was purchased from BD Biosciences
(Pharmingen division, San Diego, CA). Antibodies recognizing mouse CD49b,
CD107a, CD63, TNFα, IL-4 and IL-6 were purchased from Biolegend. Mouse anti
c-Kit, FcεRI, IL-13, MIP-1α, MCP-1, p AKT and p-SYK were purchased from
eBioscience. Mouse anti-p-ERK was purchased from BD Pharmingen (San
Diego, CA). Mouse anti-IL-33 was purchased by R&D systems. Propidium Iodide
and DNP-HSA was purchased from Sigma-Aldrich (St. Louis, MO). Caspase 3/7
kit was purchased from Immunochemistry. Cyto ID autophagy detection kit was
from Enzo Life Sciences (Farmingdale, NY). The following drugs were used:
Fluvastatin (SML0038), Simvastatin (S6196), Pravastatin (P4498), Atorvastatin
(PZ0001), Lovastatin (PHR1285), Mevalonic acid (44714), Zaragozic acid A
(Z2626), all from Sigma-Aldrich. Farnesylation transferase inhibitor III (FPTIII)
and geranylgeranyl transferase inhibitor-286 (GGTI-286) were purchased from
Calbiochem (Darmstadt, Germany). Farnesyl diphosphate and geranyl geranyl
diphosphate were purchased from Echelon (Salt Lake city, UT). Wnt5a and
Leptin were purchased from R&D systems (Minneapolis, MN).
Peritoneal mast cell culture
Peritoneal lavage was performed on C57BL/6 and 129/sv mice. Cells were
harvested and cultured in cRPMI (as described above) containing IL-3 and SCF
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at 10ng/ for 5 days to allow for expansion of mast cells. Mast cells were positively
selected and separated using the EasySep Magnet from StemCell Technologies
(Vancouver, BC) using c-Kit as a positive marker of mast cells. Flow cytometry
was used as confirmation of mast cells.
Cytokine measurement
BMMC treated with fluvastatin or DMSO were cultured in cRPMI 1640 with 10
ng/mL IL-3 and SCF +/- 0.5 µg/mL IgE for 24 hours at a concentration of 1x106
cells/m. BMMC were washed in PBS, resuspended at 1x106 cells/mL in cRPMI
1640 with 10 ng/mL IL-3 and SCF +/- 50 ng/mL DNP-HSA for 16 hours, after
which supernatants were taken. IL-6, IL-13, TNF-α, and MCP-1 supernatant
levels were measured by ELISA kits (Biolegend). ELISAs were developed using
BD OptEIA reagents from BD Biosciences.
Flow cytometric analysis
Surface expression of c-Kit and FcεRI were measured by flow cytometry on a BD
FACScalibur. BMMC were cultured in fluvastatin at 10µm/ml or DMSO at varying
concentrations for varying times. Cells were then washed in PBS. For directlylabelled antibody staining, cell pellets were incubated in 10µL 2.4G2 rat antimouse FcγRII/III culture supernatant with PE- anti-c-Kit and FITC- anti-FcεRI,
then incubated for 30 minutes at 4°C, washed in FACS buffer (PBS, 3% FBS,
0.1% Sodium Azide), and analyzed by flow cytometry.
In-cell staining for cytokines
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Cells treated with 10µm/ml fluvastatin or DMSO ± IgE at 0.5µg/ml for 24 hours
were washed and resuspended in cRPMI containing IL-3 and SCF at 10ng/ml.
BMMC were given DNP-HSA for 90 minutes, then treated with 5µM Monensin for
8 hours, fixed in 4% paraformaldehyde, washed twice in PBS and stored
overnight at 4°C. Cells were then pelleted and resuspended in saponin buffer
(PBS, 0.1% BSA, 0.01M HEPES, 0.5% saponin) for 20 minutes at room
temperature. Cell pellets were incubated in 10 µL 2.4G2 rat anti-mouse FcγRII/III
culture supernatant with APC- or PE -anti- TNF, IL-6, IL-13, MCP-1, MIP-1, IL-33
or IL-4 in saponin buffer at 4°C for 30 minutes. Basophils were also stained with
Fitc- anti-CD49b as a marker of basophils prior to fixation.
Degranulation assays
Cells plated at 1x106 cells/mL in cRPMI (as described above) and treated with
fluvastatin or DMSO for 24 hours ± 0.5 µg/ml of IgE, were washed twice in RPMI
and activated ± DNP-HSA for 1 hour and then stained with CD107a or CD63 for
45 minutes at 4°C. cells were then washed twice in FACS buffer and analyses by
flow cytometry.
Cell death
Cells were treated with 5µM, 10µM, 20µM or 40µM fluvastatin for 1 to 4 days,
then assessed for cell death via caspase-3/7 staining using the methods
described in the millipore kit. PI-exclusion yields a live versus dead
determination. Prepare Propidium iodide solution to 200 µl/ ml and add 10
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microlitres per 200 µl of cells (resuspended at 1x106 cells/mL) and run by flow
cytometry.
Autophagy detection
For autophagy detection using Cyto ID the detection kit, BMMC were
resuspended at 5x105 cells/mL and treated with 5 µM, 10 µM, 20 µM and 40 µM
fluvastatin for 1-3 days, then pelleted and stained with the Cyto ID kit using the
method described in the kit.
Migration assay
8 µm polycarbonate 24-well transwell inserts from Corning will be coated in BSA,
plates were incubated for 1 hour at 37°C. BMMC were resuspended at 2x106
cells/mL in FBS-free cRPMI for 2 hours. Bottom chambers contained 850 µL of
FBS-free cRPMI with IL-3 at 0.5 ng/mL +/- 50 ng/mL SCF in the bottom well and
200 µL of the previously starved BMMC supplemented with 0.5 ng/mL IL-3 in the
upper well. Cells were then incubated for 16 hours at 37°C, then counted using
flow cytometry with propidium-iodide exclusion staining. Fold of control was
calculated for all groups.
HMG-CoA reductase qPCR
BMMCs were cultured with or without 40 µM fluvastatin for 6 hours. Then,
cells were harvested and total RNA was extracted with TRIzol reagent (Life
Technologies, Grand Island, NY). cDNA was synthesized using the qScript
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microRNA cDNA Syntheis Kit (Quantabio, Gaithersburg, MD) following the
manufacturer’s protocol using oligo dT primers provided in the kit. cDNA was
quantified

using

the

Spectrophotometer

Thermo

(Thermo

Scientific

Scientific,

NanoDrop™

Waltham,

MA)

1000

UV–vis

according

to

manufacturer’s recommended protocol. qPCR analysis was performed with Bio
Rad CFX96 Touch™ Real-Time PCR Detection System (Hercules, CA) and
SYBR® Green detection using a relative Livak Method. Each reaction was
performed according to the manufacturer’s protocol using 8ng of sample cDNA,
12.5 µl of PerfeCTa SYBR Green SuperMix (Quantabio, Gaithersburg, MD) and
mmu-miR-155

or

SNORD47

(housekeeping

gene)

primers

(Quantabio,

Gaithersburg, MD) in a final reaction volume of 10 µM. Amplification conditions
for all reactions consisted of a heat-activation step at 95 °C for 15 min followed
by 40 cycles of 95 °C for 15 s, 60 °C for 30 s and 70 °C for 15 s. Fluorescence
data was collected during the extension step of the reaction.
Western blot analysis
Western blotting was performed using 50µg total cellular protein per sample.
Protein was loaded and separated over 8–16% or 4–20% gradient SDS
polyacrylamide gels (Bio-Rad, Hercules, CA). Proteins were transferred to
nitrocellulose membranes (Pall Corporation, Ann Arbor, MI), and blocked for 60
minutes in Blotto B buffer (Rockland Immunochemicals, Gilbertsville, PA) plus
0.1% Tween-20. Blots were incubated in a solution of TBS supplemented with
0.1% Tween-20 and 5% BSA (TBST), with the indicated antibodies overnight at
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4°C with gentle rocking. Blots were washed six times for 10 minutes each in
TBS-T, followed by incubation in Blotto B containing a 1:5,000 dilution of HRP
linked anti-IgG matched to the relevant species, from Cell Signaling (Danvers,
MA). Size estimates for proteins were obtained using molecular weight standards
from Bio-Rad (Hercules, CA).
Statistical Analysis
Data presented are the mean ± SEM of at least 3 independent experiments. P
values were calculated by paired or unpaired, two-tailed Student’s t test as
appropriate. P values of <0.05 were considered statistically significant using
GraphPad Prism software.
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CHAPTER 3 – RESULTS:
The effect of statins on IgE activated BMMC’s
Simvastatin and lovastatin are the most commonly prescribed statin for
the treatment of dyslipidemia. It has previously been shown that lovastatin alters
isoprenoid generation in rat basophil leukemia cells (RBL-2H3) (32). We panned
for a range of statins, in addition to lovastatin; to assess which exert the largest
response on IgE activated mast cells. C57BL/6 bone marrow derived mast cells
(BMMC’s) were pretreated for 24 hours with lipophilic statins

(lovastatin,

simvastatin, atorvastatin, pitavastatin and fluvastatin) and the hydrophobic statin
(pravastatin). BMMC’s treated with lipophilic statins significantly suppressed IgE
mediated mast cell IL-6, TNFα and IL-13 (Figure 5) production, with the
exception of atorvastatin. The hydrophobic pravastatin showed no significant
effects on cytokine production but actually slightly enhanced IL-6 and TNFα.
Fluvastatin, simvastatin and lovastatin were the most effective at suppressing
cytokine production but fluvastatin elicited the strongest response and is the
focus of this study.
To determine the kinetics for the effects of fluvastatin on IgE mediated
cytokine production, we conducted a time course (Figure 6), and dose response
(Figure 7) assays for IL-6, TNFα and IL-13. We established that the effect of
fluvastatin on mast cell cytokine production is dose dependent and that 10µM
fluvastatin suppressed cytokine production on average 50%. Fluvastatin cultured
for 24-hours yielded significant suppression of pro-inflammatory cytokines and
while suppression is greatest at 72 hours, a large portion of cells are dead at this
	
  

27	
  

	
  
point. Interestingly, fluvastatin has no effect on IL-10 production (Figure 8), which
in many cases is seen as an anti-inflammatory chemical mediator.
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Figure 5
Fluvastatin suppress cytokine production from IgE activated mast cells to a
greater extent than other statins.
IgE primed C57BL/6 BMMC’s were cultured in IL-3 and SCF, with or without
DMSO or 10 µM statin and then activated with DNP-HSA for 16 hours.
Supernatants were collected as described in the methods and materials and
assessed by standard sandwich ELISA to determine A) IL-6, B) TNFα, C) IL-13
concentrations. The results are expressed as the mean ± SEM of at least 3
independent experiments conducted in triplicate.
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Figure 6
Fluvastatin suppresses IgE activated BMMC’s in a dose dependent manner.
IgE primed C57BL/6 BMMC’s were cultured in IL-3 and SCF, with or without
fluvastatin or DMSO and then activated with DNP-HSA for 16 hours.
Supernatants were collected as described in the methods and materials and
assessed by standard sandwich ELISA to determine A) IL-6, B) TNFα, C) IL-13
concentrations. The results are expressed as the mean ± SEM of at least 3
independent experiments conducted in triplicate.
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Figure 7
Fluvastatin suppression of IgE activated BMMC’s increases with time.
IgE primed BMMC’s were cultured in IL-3 and SCF, with or without fluvastatin 10
µM or DMSO for the stipulated time periods and then activated with DNP-HSA for
16 hours. Supernatants were collected as described in the methods and
materials and assessed by standard sandwich ELISA to determine A) IL-6, B)
TNFα, C) IL-13, D) MCP-1 concentrations. The results are expressed as the
mean ± SEM of at least 3 independent experiments conducted in triplicate.
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Figure 8
Fluvastatin does not alter IgE mediated IL-10 production in BMMC’s
IgE primed C57BL/6 BMMC’s were cultured in IL-3 and SCF, with or without a
given 10 µM fluvastatin or DMSO and then activated with DNP-HSA for 16 hours.
Supernatants were collected as described in the methods and materials and
assessed by standard sandwich ELISA to determine IL-10 concentration. The
Graph is a representation of 3 independent experiments with an n=9. Data shown
are mean ± SEM.
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The effect of fluvastatin on peritoneal mast cells
Thus far, we have showed that fluvastatin suppresses pro inflammatory cytokines
on BMMC’s that have been cultured in vitro in IL-3 and SCF. To determine if ex
vivo mast cells respond in the same way as BMMC’s cultured with fluvastatin we
assayed peritoneal mast cells. We conducted peritoneal lavage and cultured
cells in IL-3 and SCF for 3 days and then isolated and purified the mast cell
populations. IgE sensitized mast cells were then cultured in fluvastatin for 24
hours and activated with antigen (DNP-HSA). Here, we show that mast cells
cultured ex vivo when treated with fluvastatin suppress cytokine production in the
same way as in vitro cultures BMMC’s. (Figure 9-10).
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Figure 9
Fluvastatin suppress IL-6 and TNFα production from IgE activated
peritoneal mast cells.
Peritoneal mast cells were separated using easySep magnet selecting for c-kit
positive cells. Mast cells were then cultured in IL-3 and SCF with or without
fluvastatin or DMSO in IgE over night and then activated with DNP-HSA for 16 h
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and supernatants were collected as described in the methods and materials. A)
IL-6, B) TNFα. The results are expressed as the mean ± SEM of at least 3
independent experiments conducted in triplicate.
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Figure 10
Fluvastatin suppress IL-13 and MCP-1 production from IgE activated
peritoneal mast cells.
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Peritoneal mast cells were separated using easySep magnet selecting for c-kit
positive cells. Mast cells were then cultured in IL-3 and SCF with or without
fluvastatin or DMSO in IgE over night and then activated with DNP-HSA for 16 h
and supernatants were collected as described in the methods and materials. A)
IL-13, B) MCP-1. The results are expressed as the mean ± SEM of at least 3
independent experiments conducted in triplicate.

	
  

37	
  

	
  
The effect of fluvastatin on FcεRI and c-kit receptor expression.
The suppressive effect of fluvastatin on C57BL/6 BMMC’s may manifest
from altered FcεRI expression. We proceeded by conducting a dose response of
fluvastatin for 4 days and assessed FcεRI expression by flow cytomentry. Here,
we show that fluvastatin treatment does not significantly alter FcεRI expression in
C57BL/6 (Figure 11) BMMC’s. We also investigated the effect of fluvastatin on ckit receptor expression since it has been shown that BMMC’s cultured with SCF
(the c-kit ligand) increase cytokine production. Our data show that fluvastatin
does not alter c-kit surface receptor expression on C57BL/6 (Figure 11) BMMC’s.
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Figure 11
Fluvastatin does not alter FcεRI or c-kit surface expression on C57BL/6
BMMC’s.
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C57BL/6 BMMC’s were treated with DMSO or fluvastatin at 5 µM, 10 µM, 20 µM
and 40 µM for 1-4 days and surface expression of A) FcεRI, B) c-kit expression
were measured by flow cytometry. The results are expressed as the mean ±
SEM of 3 independent experiments.
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The effect of fluvastatin on IgE mediated mast cell cytokine production is
counteracted by mevalonic acid (MVA)
Fluvastatin acts by blocking HMG-CoA reductase and inhibiting the
production of mevalonic acid (MVA). To assess fluvastatin’s target specificity we
treated BMMC’s with fluvastatin and MVA to see if MVA reversed the effects of
fluvastatin. Here, we show that fluvastatin suppresses IgE mediated mast cell
production of pro inflammatory cytokines and chemokines and is rescued by
mevalonic acid treatment (Figure 12-13).
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Figure 12
Fluvastatin induced suppression of IgE mediated cytokine production in
mast cells is rescued by mevalonic acid.
C57BL/6 BMMC’s were cultured in IL-3 and SCF, with or without fluvastatin 10
µM or DMSO for 24 h with or without mevalonic acid 1000 µM and IgE
sensitized. Mast cell cultures were washed in PBS and then treated again with
fluvastatin 10 µM or DMSO for 24 h with or without mevalonic acid and then
given DNP-HSA for 16 h and supernatant taken for ELISA. A) IL-6, B) TNFα, C)
IL-13. The Graph is a representation of 3 independent experiments with an n=9.
Data shown are mean ± SEM.
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Figure 13
Fluvastatin induced suppression of IgE mediated chemokine production in
mast cells is blunted by mevalonic acid.
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C57BL/6 BMMC’s were cultured in IL-3 and SCF, with or without fluvastatin 10
µM or DMSO for 24h with or without mevalonic acid 1000 µM and IgE sensitized.
Mast cell cultures were washed in PBS and then treated again with fluvastatin 10
µM or DMSO for 24 h with or without mevalonic acid and then given DNP-HSA
for 16 hours and supernatant taken for ELISA. A) MCP-1, B) MIP-1α. The Graph
is a representation of 3 independent experiments with an n=9. Data shown are
mean ± SEM.
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The effect geranylgeranyl pyrophosphate inhibitor and farnesyl pyrophosphate
inhibitor on IgE mediated mast cell cytokine production.
MVA continues to be metabolized to the farnesyl pyrophosphate and
geranylgeranyl pyrophosphate, which leads to the production of prenylated
proteins, which include the small GTPases such as Ras, Rac, Rho and CDC42.
Thus, we investigated the effects of GGTI-286 and FPTIII, which selectively
inhibit geranylgeranylation and farnesylation respectively. Here, we show that IgE
sensitized mast cells pretreated with GGTI-286 for 24 hours significantly inhibit
IgE induced cytokine production to a similar degree as fluvastatin treated mast
cells (Figure 14-15). Treatment with fluvastatin and GGTI-286 suppress cytokine
production more significantly that either drug alone. FPTIII treated mast cells
show cytokine suppression to a lesser extent that fluvastatin for IL-6 and MCP-1
(Figures 14, and 15 respectively). For TNFα, IL-13 and MIP-1α FPTIII shows no
significant suppression (Figures 14-15 respectively). Additionally, BMMC’s
treated with both fluvastatin and FPTIII show suppressed cytokine levels to the
same extent as fluvastatin alone, suggesting that the FPTIII arm of the
cholesterol biosynthesis pathway does not significantly contribute to cytokine
suppression. These data suggest that fluvastatin suppression of antigen induced
cytokine production alters geranylgeranylation more so that farnesylation.
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Figure 14
GGTI-286 significantly suppresses Ag induced cytokine production on
BMMC and FPTIII to a lesser extent.
C57BL/6 BMMC’s were cultured in IL-3 and SCF and IgE sensitized and
pretreated with or without DMSO, fluvastatin 10 µM, GGTI-266 20 µM or FPTIII
20 µM or combinations for 24 hours and then stimulated with DNP-HSA
(50ng/ml) for 16 hours. Supernatants were harvested and ELISA’s were
preformed. A) IL-6, B) TNFα, C) IL-13. The Graph is a representation of at least 4
independent experiments with an n=12. Data shown are mean ± SEM.
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Figure 15
GGTI-286 and FPTIII suppress Ag induced chemokine production on
BMMC.
C57BL/6 BMMC’s were cultured in IL-3 and SCF and IgE sensitized and
pretreated with or without DMSO, fluvastatin 10 µM, GGTI-266 20 µM or FPTIII
20 µM or combinations for 24 hours and then stimulated with DNP-HSA
(50ng/ml) for 16 hours. Supernatants were harvested and ELISA’s were
preformed. A) MCP-1, B) MIP-1α. The Graph is a representation of at least 4
independent experiments with an n=12. Data shown are mean ± SEM.

	
  

48	
  

	
  
The effect of geranylgeranyl pyrophosphate (GPP) and farnesyl pyrophosphate
(FPP) on IgE mediated mast cell cytokine production in response to Fluvastatin
treatment
Inhibition of MA also alters production of the intermediate isopreniods
GGPP and FPP. GGPP and FPP have been shown to affect posttranslational
modification of signaling molecules including small G-proteins(25). GGPP is
known solely for the production of prenylated proteins such as Rac Rho and
Cdc42. FPP on the other hand, leads to the production of sterol and non-sterol
products in addition to prenylation such as Ras. We therefore, sought to
investigate which branch of the isoprenoid pathway was responsible for cytokine
production suppression in mast cells. Following treatment with GGTI-286 and
PTIII we shows that GGTI-286 treatment mimicked fluvastatin treated mast cells,
suggesting fluvastatin acts by blocking production of geranylgeranylated proteins
more so than farnesylated proteins. We then wanted to treat mast cells with
exogenous GGPP and FPP and see if these treatments restored cytokine
production in fluvastatin treated cells. Here, we show that treatment of IgE
sensitized mast cells activated with antigen and pretreated with either GGPP or
FPP has little effect to no effect on cytokine production (Figure 16-17). Treating
mast cells with GGPP and fluvastatin shows a partial rescue of cytokine
production in relation to fluvastatin alone treated mast cells, suggesting that
fluvastatin

acts

predominately

by

blocking

geranylgeranylated

proteins.

Treatment of fluvastatin with FPP shows little to no rescue of cytokine production
in relation to fluvastatin alone treated mast cells (Figure 16-17). In addition
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treatment of fluvastatin, GGPP and FPP are not statistical difference that
fluvastatin and GGPP treated cells for IL-6, TNFα (Figure 16), IL-13 and MCP-1
(Figure 17).
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Figure 16
Geranylgeranyl pyrophosphate (GGPP) partially rescues Antigen induced
IL-6 and TNFα production from fluvastatin treated BMMC’s. C57BL/6
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BMMC’s were cultured in IL-3 and SCF and IgE sensitized and pretreated with or
without DMSO, fluvastatin 10 µM, GGPP 20 µM or FPP 20 µM or combinations
for 24 hours and then stimulated with DNP-HSA (50ng/ml) for 16 h. Supernatants
were harvested and ELISA’s were preformed. A) IL-6, B) TNFα. The Graph is a
representation of 3 independent experiments with an n=9. Data shown are mean
± SEM.
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Figure 17
Geranylgeranyl pyrophosphate (GGPP) partially rescues Antigen induced
IL-13 and MCP-1 production from fluvastatin treated BMMC’s. C57BL/6
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BMMC’s were cultured in IL-3 and SCF and IgE sensitized and pretreated with or
without DMSO, fluvastatin 10 µM, GGPP 20 µM or FPP 20 µM or combinations
for 24 h and then stimulated with DNP-HSA (50ng/ml) for 16 h. Supernatants
were harvested and ELISA’s were preformed. A) IL-13, B) MCP-1. The Graph is
a representation of 3 independent experiments with an n=9. Data shown are
mean ± SEM.

	
  

54	
  

	
  
The effect of zaragozic acid A on BMMC’s cytokine production.
Thus far, we have demonstrated that isoprenoid generation is critical for
IgE Induced cytokine production. We next investigated the potential role of
cholesterol in the suppression of cytokines without altering isoprenoid production.
To achieve this, we used the squalene synthase inhibitor zaragozic acid A (ZA),
which blocks cholesterol synthesis downstream of isoprenoid synthesis. Here, we
show that BMMC’s treated with ZA does not alter cytokine production (Figure 18)
and propose that fluvastatin’s method of suppressing cytokines is independent of
cholesterol.
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Figure 18
Zaragozic acid A does not alter cytokine production of IgE sensitized and
Antigen activated BMMC’s.
C57BL/6 BMMC’s were cultured in IL-3 and SCF and IgE sensitized and
pretreated with or without DMSO or zaragozic acid A (ZA) for 24 h and then
stimulated with DNP-HSA (50 ng/ml) for 16 h. Supernatants were harvested and
ELISA’s were preformed. A) IL-6, B) TNFα, C) IL-13. The Graph is a
representation of 3 independent experiments with an n=9. Data shown are mean
± SEM.
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Figure 19
T helper cell differentiation.
T helper cells are characterized by distinct cellular function and cytokine
secretion. Their subsets also account for different immune pathologies and
atopy. Whilst there are many more T cell subsets than shown, we will focus on
genetic strains that are predisposed to generating a Th1 prone (C57BL/6)
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immune response or a Th2 prone (129/sv) immune response, Th2 prone mice
being more susceptible to asthma and allergy.
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The effect of fluvastatin on IgE activated mast cells: genetic influence
Thus far, we have demonstrated that fluvastatin suppresses antigeninduced cytokine production on C57BL/6 mice, which are Th1 prone. To
determine if genetic background alters fluvastatin responsiveness we looked at
129/sv mice, which are Th2 prone in comparison to C57BL/6 mice. As shown in
Figure 20, (TNFα, IL-13 and MCP-1 respectively) the Th1 prone C57BL/6 mice
show suppression of cytokines. Interestingly, the Th2 prone 129/sv mice show
resistance to fluvastatin treatment when assessing cytokine production. We
further demonstrate that C57BL/6 mice treated with fluvastatin or ZA suppress
cholesterol levels, whereas 129/sv mice treated with fluvastatin or ZA do not alter
cholesterol levels (Figure 21).
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Figure 20
Fluvastatin suppress TNFα, IL-13 and MCP-1 production from IgE activated
BMMC’s from 129/sv IgE sensitized BMMC’s were cultured in IL-3 and SCF with
or without fluvastatin at 5 µM, 10 µM and 40 µM for 24 h and then activated with
antigen for 16 h. Supernatants were collected as described in the methods and
materials. A) TNFα, B) IL-13, C) MCP-1. The results are expressed as the mean
± SEM of 3 independent experiments.
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Figure 21
Fluvastatin and zaragozic acid suppress cholesterol production on the
C57BL/6 background but not the 129/sv BMMC’s.
C57BL/6 and 129/sv BMMC’s were cultured in IL-3 and SCF with or without
fluvastatin or ZA for 24 h spun down and resuspended in PBS. Cholesterol levels
were measured using mass spectrometry.
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The effect of fluvastatin on intracellular cytokine versus extracellular cytokine
secretion.
We have shown that fluvastatin suppresses cytokine secretion. We next
wanted to evaluate fluvastatin’s ability to alter intracellular cytokine production via
in cell staining. It may be that mast cells treated with fluvastatin make the same
levels of cytokines, but have defects in pathways that transport these chemical
mediators. We therefore compared intracellular cytokine production, to secreted
cytokines. Our data show that fluvastatin suppresses intracellular IL-6 (Figure 22)
and TNFα (Figure 23) production in addition to secreted cytokines on the
C57BL/6 Th1 prone genetic background but not the 129/sv Th2 prone
background. These data suggest that fluvastatin does not just impede secretion,
but also generation of these cytokines.
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Figure 22
Fluvastatin suppresses IL-6 on C57BL/6 BMMC’S intracellularly and
extracellularly but 129/sv BMMC’S are resistant.
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IgE sensitized C57BL/6 and 129/sv BMMC’s were cultured in IL-3 and SCF with
or without fluvastatin or DMSO A) cells were then activated with antigen for 90
minutes and then cultured with monensin for 6 hours and fixed in 4%
paraformaldehyde. Cells were then permeabilized in saponin buffer and
intracellularly stained with PE-anti IL-6. B) Cells were then activated with antigen
for 16 hours, supernatants were harvested and ELISA’s run. The results are
expressed as the mean ± SEM of 2 independent experiments n=6.
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Figure 23
Fluvastatin suppresses TNFα on C57BL/6 BMMC’S intracellularly and
extracellularly but 129/sv BMMC’S are resistant.
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IgE sensitized C57BL/6 and 129/sv BMMC’s were cultured in IL-3 and SCF with
or without fluvastatin or DMSO A) cells were then activated with antigen for 90
minutes and then cultured with monensin for 6 hours and fixed in 4%
paraformaldehyde. Cells were then permeabilized in saponin buffer and
intracellularly stained with PE-anti TNFα. B) Cells were then activated with
antigen for 16 h, supernatants were harvested and ELISA’s run.
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Additional Th1 and Th2 prone genetic strains
In addition to the Th2 prone 129/sv mice we looked at the Th2 prone
Balb/c mice. Here, we show that Balb/c BMMC’s are also resistant to fluvastatin,
when assessing IgE induced cytokine production (Figure 24) but 129/sv and
Balb/c mice did not show resistance to GGTI (Figure 25-26). Another Th2 prone
strain the A/J mice. When looking at A/J’s ability to produce cytokine in response
to antigen, we see a variation. For IL-6 production, overall we see a slight
suppression at 5 µM but for higher fluvastatin concentrations of 20 µM we see a
slight enhancement (Figure 27). For TNFα (Figure 27 B) we see suppression
with increasing concentration of fluvastatin.

When looking at C3H/HeJ mice

whose genetic background is Th1 prone, we show that IL-6 (Figure 28) and
TNFα (Figure 28B) production is suppresses.
We next compared peritoneal mast cells of A/J, and C3H/HeJ in
comparison to C57BL/6 and 129/sv. Here, we show that whilst the peritoneal
mast cells for C57BL/6 show suppression, 129/sv show resistance to fluvastatin
treatment where as the A/J, and C3H/HeJ peritoneal mast cells do not show the
same Th1 and Th2 prone responses (Figure 29). Previously, we have shown that
fluvastatin does not suppress IL-10 production on C57BL/6 BMMC’s. We next
looked at IL-10 production on peritoneal mast cells from C57BL/6 and 129/sv
interestingly show enhancement (Figure 30). These data suggest that fluvastatin
resistance that is evident on some Th2 genetic backgrounds is not all-inclusive
and is more complex than simply a Th1 versus a Th2 genetic background.
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Figure 24
Fluvastatin does not suppress IgE activated cytokine or chemokine
production from Balb/c BMMC’s.
Balb/c IgE sensitized BMMC’s were cultured in IL-3 and SCF, with or without
fluvastatin or DMSO and then activated with DNP-HSA for 16 h and supernatants
were collected as described in the methods and materials. A) IL-6, B) TNFα, C)
IL-13, D) MCP-1. The results are expressed as the mean ± SEM of 3
independent experiments.
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Figure 25
GGTI-286 significantly suppresses Ag induced cytokine production on
129/sv BMMC’s but fluvastatin does not.
129/sv BMMC’s were cultured in IL-3 and SCF and IgE sensitized and pretreated
with or without DMSO, Fluvastatin 10 µM, GGTI-266 20 µM or FPTIII 20 µM or
combinations for 24 h and then stimulated with DNP-HSA (50 ng/ml) for 16 h.
Supernatants were harvested and ELISA’s were preformed. A) IL-6, B) TNFα, C)
MCP-1. The Graph is a representation of 4 independent experiments with an
n=12. Data shown are mean ± SEM.
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Figure 26
GGTI-286 and FPTIII significantly suppresses Ag induced cytokine
production on Balb/c BMMC’s but fluvastatin does not.
Balb/c BMMC’s were cultured in IL-3 and SCF and IgE sensitized and pretreated
with or without DMSO, fluvastatin 10 µM, GGTI-266 20 µM or FPTIII 20 µM or
combinations for 24 h and then stimulated with DNP-HSA (50 ng/ml) for 16
hours. Supernatants were harvested and ELISA’s were preformed. A) IL-6, B)
TNFα, C) MCP-1. The Graph is a representation of 4 independent experiments
with an n=12. Data shown are mean ± SEM.
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Figure 27
Fluvastatin does not suppress IgE activated IL-6 production But does
suppress TNFα, additionally Fluvastatin does not suppress consistently
suppress IgE activated IL-13 production from A/J BMMC’s.
IgE sensitized A/J BMMC’s were cultured in IL-3 and SCF, with or without
fluvastatin or DMSO and then activated with DNP-HSA for 16 h and supernatants
were collected as described in the methods and materials. A) IL-6, B) TNFα, C)
IL-13. The results are expressed as the mean ± SEM of 2 independent
experiments.
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Figure 28
Fluvastatin mediated suppression of IL-6 and TNFα by IgE activated mast
cells increases with dose on C3H/HeJ.
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IgE sensitized C3H/HeJ BMMC’s were cultured in IL-3 and SCF, with or without
fluvastatin or DMSO and then activated with DNP-HSA for 16 h and supernatants
were collected as described in the methods and materials. A) IL-6, B) TNFα. The
results are expressed as the mean ± SEM of 2 independent experiments.
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Figure 29
The effect of fluvastatin from IgE activated peritoneal mast from C57BL/6,
129/sv, C3H/HeJ and A/J.
Peritoneal mast cells were separated using easySep magnet selecting for c-kit
positive cells. IgE sentitized mast cells were then cultured in IL-3 and SCF with or
without fluvastatin or DMSO and then activated with DNP-HSA for 16 h and
supernatants were collected as described in the methods and materials. A) IL-6,
B) TNFα and C) shows IL-13 production. The results are expressed as the mean
± SEM of 3 independent experiments.
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Figure 30
Fluvastatin shows no suppression of IL-10 in C57BL/6 peritoneal mast cells
but actually enhances IL-10 production in 129/sv peritoneal mast cells.
Peritoneal mast cells from C57BL/6 and 129/sv mice were separated using
easySep magnet selecting for c-kit positive cells. IgE sensitized mast cells were
then cultured in IL-3 and SCF with or without fluvastatin or DMSO and then
activated with DNP-HSA for 16 h and supernatants were collected as described
in the methods and materials. The results are expressed as the mean ± SEM of 3
populations.
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Fluvastatin effect on mast cell degranulation
It has previously been shown that fluvastatin suppresses mast cell
degranulation (26) in RBL-2H3 cells. Here, we show that fluvastatin suppresses
mast cell degranulation on C57BL/6 BMMC’s but not Th2 prone 129/sv BMMC’s
(Figure 31) demonstrating that fluvastatin resistance on 129/sv BMMC’s extends
beyond cytokine production.
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Figure 31
Fluvastatin suppresses mast cell degranulation from C57BL/6 but not
129/sv BMMC’s. C57BL/6 and 129/sv IgE sensitized BMMC’s were cultured in
IL-3 +SCF with fluvastatin or DMSO for 24 h and then activated for 1 h with
antigen. Cells were then stained for CD63 for 45 minutes and then run by flow
cytometry.
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Fluvastatin and migration
SCF induces chemotactic migration of mast cells and is important for
survival and proliferation. We wanted to assess the potential for fluvastatin to
suppress mast cell migration by setting up a transwell assay. It has previously
been show that C57BL/6 BMMC’s migrate to SCF for 24 hours suppresses
BMMC migratory capabilities. Here, we compare C57BL/6 and 129/sv BMMCs
ability to migrate towards SCF and show that the Th2 prone 129/sv BMMC’s are
resistant to the suppressive capabilities of fluvastatin (Figure 32).
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Figure 32
Fluvastatin suppresses mast cell migration of C57BL/6 BMMC’s but not
129/sv BMMC’s.
C57BL/6 and 129/sv BMMC’s were tested through 8 µm transwell membranes for
migration in response to SCF or fluvastatin as describes in methods and
materials. Fold migration is based on comparison to media alone samples. The
results are expressed as the mean ± SEM of 2 independent experiments.
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Fluvastatin elicits cell death in C57BL/6 BMMC’s more so than 129/Sv BMMC’s.
We next wanted to assess the effect of fluvastatin on mast cell death by
looking at dead cells (Figure 33), apoptosis (Figure 34) and autophagy (Figure
35) on C57BL/6 and 129/sv mice (Figure 36), apoptosis (Figure 37) and
autophagy (Figure 38) by flow cytometry as a time course assay. Here, we show
that C57BL/6 mice show increased cell death, apoptosis and autophagy is a
dose dependent manner after 3 days of fluvastatin treatment whereas 129/sv
BMMC’s show resistance.
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Figure 33
Fluvastatin enhances mast cell death in C57BL/6 mice in a dose dependent
way over 3 days.
C57BL/6 BMMC’s were cultured with 5 µM, 10 µM, 20 µM or 40 µM fluvastatin for
1 through 3 days and then stained with propidium iodide 200 µL (PI exclusion) a
few seconds before running by flow cytometry. The results are expressed as the
mean ± SEM of n=6.
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Figure 34
Fluvastatin enhances mast cell apoptosis in C57BL/6 mice in a dose
dependent way over 3 days.
C57BL/6 BMMC’s were cultured with 5 µM, 10 µM, 20 µM or 40 µM fluvastatin for
1 through 3 days and then stained with caspase 3/7 green detection reagent for
45 minutes and then run by flow cytometry. The results are expressed as the
mean ± SEM of n=3.
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Figure 35
Fluvastatin enhances mast cell autophagy in C57BL/6 mice in a dose
dependent way over 3 days.
C57BL/6 BMMC’s were cultured with 5 µM, 10 µM, 20 µM or 40 µM fluvastatin for
1 through 3 days and then stained with CytoID autophagy kit as describes in
methods and materials. Samples were run by flow cytometry. The results are
expressed as the mean ± SEM of n=6.

	
  

83	
  

	
  
100

% Death

80

60

40

NS
NS

**

NS

NS

**

**

NS

20

40
µM

20
µM

Fl
uv
a

10
µM

5µ

Fl
uv
a

a

Fl
uv
a

M

F
uv

IL

Day 1

Fl

-3

+S

C

θ

40
µM

Fl
uv
a

20
µM

10
µM

Fl
uv
a

5µ

Fl
uv
a

a
uv
Fl

IL

-3

+S

C

θ

F

M

0

Day 3

Figure 36
Fluvastatin enhances mast cell death in 129/Sv mice in a dose dependent
way over 3 days.
129/sv BMMC’s were cultured with 5 µM, 10 µM, 20 µM or 40 µM fluvastatin for 1
through 3 days and then stained with propidium iodide 200 µL (PI exclusion) a
few seconds before running by flow cytometry. The results are expressed as the
mean ± SEM of n=6.
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Figure 37
Fluvastatin enhances mast cell apoptosis in 129/SvImJ mice in a dose
dependent way over 3 days.
129/sv BMMC’s were cultured with 5 µM, 10 µM, 20 µM or 40 µM fluvastatin for 1
through 3 days and then stained with caspase 3/7 green detection reagent for 45
minutes and then run by flow cytometry. The results are expressed as the mean
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Figure 38
Fluvastatin enhances mast cell autophagy in 129/sv mice in a dose
dependent way over 3 days.
129/sv BMMC’s were cultured with 5 µM, 10 µM, 20 µM or 40 µM fluvastatin for 1
through 3 days and then stained with CytoID autophagy kit as describes in
methods and materials. Samples were run by flow cytometry. The results are
expressed as the mean ± SEM of n=6.
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The effect of fluvastatin on antigen stimulated basophils
To this point, we have investigated the suppressive capabilities of
fluvastatin on mast cell function with particular emphasis on IgE signaling and
cytokine production. Basophils express the FcεRI and upon aggregation of this
receptor are capable of producing a similar range of chemokine’s and cytokines.
We therefore decided to investigate the potential suppressive abilities of
fluvastatin on basophils from a C57BL/6 and 129/sv genetic backgrounds. Here,
we show that IgE sensitized basophils activated with antigen from a C57BL/6
background pretreated with fluvastatin for 24 h show suppression of IL-4, IL-6, IL13 (Figure 39). The suppression of IL-6 (Figure 39 B) and TNFα (Figure 40 A) on
the C57BL/6 and the cytokine production in general is less so, but still evident.
MCP-1 (Figure 40 B) and MIP-1α (Figure 40 C) show similar trends. However,
no significant suppression of cytokines or chemokines is evident in the Th2 prone
129/sv treated with fluvastatin.
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Figure 39
Fluvastatin suppress IL-4, IL-6 and IL-13 production from IgE activated
basophils on a C57BL/6 but not a 129/sv genetic background.
C57BL/6 and 129/sv IgE bone marrow were cultured in IL-3 20 ng/ml for 8 days
and then cultured with or without IgE at 0.5 µg/ml, in fluvastatin 10 µm or DMSO
for 24 h. in cell staining was conducted as described in methods and materials
with CD49b as a basophil marker. A) Shows IL-4, B) shows IL-13 and C) shows
IL-6 production from basophils on a C57BL/6 and 129/sv genetic background.
The results are expressed as the mean ± SEM of n=6.
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Figure 40
Fluvastatin suppress TNFα, MCP-1 and MIP-α from IgE activated basophils
on a C57BL/6 but not a 129/sv genetic background.
C57BL/6 and 129/sv IgE bone marrow were cultured in IL-3 20 ng/ml for 8 days
and then cultured with or without IgE at 0.5 µg/ml, in fluvastatin 10 µm or DMSO
for 24 h. in cell staining was conducted as described in methods and materials
with CD49b as a basophil marker. A) Shows TNFα, B) shows MCP-1 and C)
shows MIP-α production. The results are expressed as the mean ± SEM of n=6.
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Fluvastatin effect on basophil degranulation
We, and others have shown that fluvastatin suppresses mast cell
degranulation (26) in RBL-2H3 cells, and we have shown that the suppression is
evident on C57BL/6 mice but not Th2 prone 129/sv mice. Here, we show that
fluvastatin suppresses basophil degranulation in C57BL/6 mice but not Th2
prone 129/sv mice (Figure 41).
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Figure 41
Fluvastatin suppresses basophil degranulation from C57BL/6 but not
129/sv mice. C57BL/6 and 129/sv IgE sensitized basophils were cultured in IL-3
20 ng/ml with fluvastatin or DMSO for 24 h and then activated for 1 h with
antigen. Cells were then stained for CD107a for 45 minutes and then run by flow
cytometry. The results are expressed as the mean ± SEM of n=6.
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Fluvastatin alters membrane bound Ras on C57BL/6 mice
As previously states, fluvastatin treatment does not suppress FcεRI
expression. Our data suggests that fluvastatin suppresses geranylgeraylation
more so that farneslylation. We therefore wanted to investigate the effect
fluvastatin may have on membrane bound Ras, a prenylated protein involved in
IgE mediated signaling. Here, we show suppression of membrane bound Ras on
the C57BL/6 but not 129/sv BMMC’s.
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Figure 42
Fluvastatin treatment dramatically suppresses membrane bound Ras in
C57BL/6 BMMC’s, whereas there is little difference in 129/sv BMMC’s.
BMMC’s treated with or without fluvastatin for 24 h. Cells were lysed and
cytospin. Cell membranes were collected and probed for Ras. Fyn was used as a
control. Data represents 2 Independent experiments after normalizing to Fyn.
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Fluvastatin selectively suppresses Fyn but upregulates Lyn in C57BL/6 BMMC’s
Down stream of the FcεRI, Fyn and Lyn are recruited and activated.
Both Fyn and Lyn can act as positive regulator, recruiting LAT. Additionally, Lyn
can act as a negative regulator. Here, we demonstrate that fluvastatin treatment
suppresses Fyn activation and augments Lyn activation on the C57BL/6
BMMC’s.
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Figure 43
Fluvastatin selectively suppresses Fyn and upregulate Lyn.
C57BL/6 BMMC’s were IgE primed and cultured in IL-3 and SCF, with or without
fluvastatin overnight and activated with antigen for 5 minutes, followed by cell
lysing. Lysates were blotted for Fyn and Lyn. A) Shows a representative blot for
Fyn and Lyn from two separate experiments that yielded similar results. B)
Shows quantification of Fyn analysis form two independent experiments. C)
Shows quantification of Lyn analysis form two independent experiments.
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Fluvastatin selectively suppresses ERK and STAT5 pathway
The suppressive effects of fluvastatin are evident through the
suppression of membrane Ras on C57BL/6 BMMC’s. Down stream of Fyn and
Ras, we show that fluvastatin suppresses ERK (Figure 44) a member of the MAP
kinases. Greatest suppression in fluvastatin treated C57BL/6 BMMC’s, is evident
at 5 minutes of antigen activation. Additionally, it has been shown that Stat5 is
critical for IgE mediated signaling (33-35). We therefore investigated fluvastatin
suppression of Stat5. Here, we show that fluvastatin treatment also suppresses
Stat5 expression (Figure 45) in C57BL/6 BMMC’s but has little effect on 129/sv
BMMC’s. Taken together, these data suggest a role for protein prenylation being
important for IgE induced signaling in primary BMMC’s.
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Figure 44
Fluvastatin selectively suppresses ERK on C57BL/6 BMMC’s.
C57BL/6 and 129/sv BMMC’s were IgE primed and cultured with or without
fluvastatin in IL-3 and SCF overnight and activated with or without antigen for 0,
5 and 15 minutes, followed by cell lysing. Lysates were blotted ERK and p-ERK.
A) Shows a representative blot for ERK and pERK for C57BL/6 BMMC’s from
two separate experiments that yielded similar results. B) Shows quantification of
the p-ERK/ERK ratio for C57BL/6 BMMC’s form two independent experiments.
C) Shows a representative blot for ERK and pERK for 129/sv BMMC’s from two
separate experiments that yielded similar results. D) Shows quantification of the
p-ERK/ERK ratio for 129/sv BMMC’s form two independent experiments.
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Figure 45
Fluvastatin selectively suppresses Stat5 on C57BL/6 but not 129/sv
BMMC’s.
C57BL/6 and 129/sv BMMC’s were IgE primed and cultured with or without
fluvastatin in IL-3 and SCF overnight and activated with or without antigen for 0,
5 and 15 minutes, followed by cell lysing. Lysates were blotted Stat5 and p-Stat5.
A) Shows a representative blot for Stat5 and p-Stat5 for C57BL/6 and 129/sv
BMMC’s from one experiment. B) Shows quantification of the p-Stat5/ Stat5 ratio
for C57BL/6 and 129/sv BMMC’s from one experiment.
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Fluvastatin selectively augments HmG-CoA reductase expression on 129/SvImJ
but not C57BL/6 BMMC’s.
Thus far, we have demonstrated that C57BL/6 mice are sensitive to
fluvastatin, and that 129/sv are resistant. We initially hypothesized that it might
be that 129/sv mice have an increase in MVA or that they have increased
expression of HMGCoA reductase (HMGCR). Here, we demonstrate that 129/sv
mice have increased HMG-CoA reductase levels upon treatment with fluvastatin,
in comparison to the C57BL/6 BMMC’s (Figure 46). These data suggest that the
increase in HMG-CoA reductase levels in 129/sv BMMC’s, is in part responsible
for 129/sv mice being resistant to fluvastatin.
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Figure 46
Fluvastatin selectively augments HMGCR reductase expression on 129/Sv
but not C57BL/6 BMMC’s.
Expression of HMGCR mRNA in C57BL/6 and 129/sv BMMC’s. BMMC’s were
plated at 1x106 cell ml and treated with DMSO or Fluvastatin for 6 h. mRNA
expression was determined by comparative qPCR. Data are expressed as the
mean ± SD of triplicate measurements from 2 independent experiments n=6.
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Fluvastatin suppresses passive systemic anaphylaxis on C57BL/6 mice but not
129/sv
Thus far, we have demonstrated the suppressive effects of fluvastatin in
vitro and ex vivo and that fluvastatin’s suppressive capabilities are exhibited on
the Th1 C57/BL/6 but not the Th2 129/sv mice. We next wanted to extend our
study the functional relevance of fluvastatin sensitivity on both the C57BL/6 and
129/sv mice. IgE dependent passive systemic anaphylaxis (PSA) is a mast cell
dependent process and thus, we investigated the effects of fluvastatin on mast
cells within this in vivo system. Here, we show that fluvastatin dampens PSA on
C57BL/6 mice (Figure 48 A), in a dose dependent manner (Figure 47) but, mice
treated with fluvastatin on 129/sv background continued to be fluvastatin
resistant (Figure 48 B). Plasma chemokine levels from C57BL/6 mice also show
suppression of serum MIP-1α (Figure 49) on C57BL/6 but not 129/sv mice.
These data, taken together, suggest that fluvastatin dampens the early and late
phase of mast cell dependent anaphylaxis. We were unable to fully investigate
additional cytokines and chemokines due to low serum levels.
Histamine causes bronchoconstriction, vasodilation and vascular leakage,
features observed during systemic anaphylaxis. We wanted to investigate
whether fluvastatin is affecting the vasculature in conjunction with mast cells of
the C57BL/6 mice. Here, we show that fluvastatin pretreatment 16 h before
administration of histamine does not significantly alter PSA (Figure 50). We
therefore conclude, that it is the effects fluvastatin exerts on mast cells that
causes a reduction of PSA on C57BL/6 mice.
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Figure 47
Fluvastatin dampens IgE induced PSA in C57BL/6 mice in a dose
dependent manner.
C57BL/6 mice were sensitized with 50 µg of IgE by intraperitoneal injection
overnight with or without fluvastatin at 1 mg, 0.5 mg or 0.25 mg or DMSO. Mice
were then injected with fluvastatin or DMSO the next morning and left for 90
minutes to rest. PSA was induced by intraperitoneal administration of DNP-HSA
antigen. Changes in core body temperature were measured by rectal probe at
regular intervals. (DMSO n=5), (fluvastatin 1 mg n=5), (fluvastatin 0.5 mg n=5)
and (fluvastatin 0.25 mg n=5).
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Figure 48
The effect of fluvastatin on PSA is strain dependent.
C57BL/6 mice were sensitized with 50µg of IgE by intraperitoneal injection
overnight with or without fluvastatin at 1mg, or DMSO. Mice were then injected
with fluvastatin or DMSO the next morning and left for 90 minutes to rest. PSA
was induced by intraperitoneal administration of DNP-HSA antigen. A)
Fluvastatin suppresses IgE induced PSA in C57BL/6 mice. B) Fluvastatin does
not alter IgE induced PSA in 129/sv mice. Changes in core body temperature
were measured by rectal probe at regular intervals.
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Figure 49
Plasma levels of circulating MIP-1α following IgE- induced PSA on C57BL/6
and 129/SvImJ mice.
Mice were administered fluvastatin and sensitized to IgE 16 h prior to the
induction of PSA and then again 1 h before Mice were injected i.p with antigen.
Mice were then sacrificed 4 h after the induction of PSA and cardiac puncture
was performed to assess circulating plasma MIP-1α levels. Data shown
represents the mean ± SEM. C57BL/6 DMSO mice (n=2), C57BL/6 fluvastatin
mice (n=2) 129/sv DMSO mice (n=5), 129/sv fluvastatin mice (n=5).
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Figure 50
Fluvastatin does not alter histamine induced PSA in C57BL/6 mice.
C57BL/6 mice were injected by intraperitoneal injection overnight with or without
fluvastatin at 1 mg, or DMSO. Mice were then injected with fluvastatin or DMSO
the next morning and left for 90 minutes to rest. PSA was induced by
intraperitoneal administration of histamine. Changes in core body temperature
were measured by rectal probe at regular intervals. Mice were sacrificed 4 hours
after the induction of PSA and cardiac puncture was performed to assess serum
cytokine levels.
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The variable responsiveness of fluvastatin is consistent with primary human skin
mast cells.
We extended our study of the fluvastatin induced differential production of
IgE mediated cytokines and chemokine production, to primary human skin mast
cells from five donors. Interestingly, we show a large variation in fluvastatin
responsiveness between the five donors (Figure 51). When investigating MCP-1
production we show we show suppression from as little as 18% to as much as
71% as seen using cluster analysis. With TNFα we see a variation in sensitivity
ranging from 30% to 87% suppression. These data suggest that the variability in
cytokine and chemokine suppression induced by fluvastatin may have a human
correlate.
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Figure 51
Variation in human mast cell responsiveness to fluvastatin
Mast cells cultured from human skin donors were sensitized to IgE and treated
with or without fluvastatin for 24 h. Human skin donors were then activated with
antigen for 16 hours as described in methods and materials. Supernatants were
then collected and then analyzed for the production of MCP-1 and TNF-α by
ELISA. Total of 5 donors labels sample 1-5, each in quintuplicate. A) MCP-1
chemokine levels. B) Fold of control MCP-1 levels S1=34% suppression, S2=
26% suppression, S3= 18% suppression, S4=71% suppression, S5= 54%
suppression. C) TNF-α cytokine levels. D) Fold of control TNF-α levels. S1=66%
suppression, S2= 87% suppression, S3= 80% suppression, S4=42%
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CHAPTER 4– DISCUSSION:
Statins, as HMG-CoA reductase inhibitors (36) display effects in addition
to lipid lowering and exhibit pleiotropic effects on immune cells. Given that statins
alter protein prenylation in addition to the lipid modification that occurs on many
proteins including those of the immune system, it is not surprising that statins
alter immune function. Statins display comparable biochemical properties and
effects on mevalonate, but have different structures and exhibit different
potencies. It has been shown that statins, in particular lovastatin, can inhibit
function of the RBL-2H3 cells (37) in vitro, and that fluvastatin inhibits
degranulation of RBL-2H3 cells (26) in vitro. Furthermore, cerivastatin and
atorvastatin have been shown to suppress growth and IgE-mediated histamine
release in human basophils (38).
This study establishes that a range of statins inhibit IgE-induced cytokine
production from Th1-prone C57BL/6 BMMC’s with varying degrees. There were
some exceptions to this: pravastatin slightly enhanced cytokine production, and
atorvastatin produced no significant effect. While atorvastatin has been shown to
strongly suppress human mast cell degranulation in vitro (39), pravastatin’s
effects may be due to its hydrophilic properties preventing it from permeating the
cell surface membrane to the extent of more lipophilic statins such as
simvastatin, lovastatin and fluvastatin (40). This being said, the most lipophilic
statins, lovastatin and simvastatin (41), whilst demonstrating significant
suppression, do not display the greatest suppression. Additionally, we
demonstrate that fluvastatin; a moderately lipophilic statin, suppresses cytokine
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production with the strongest effect and in a dose dependent manner on primary
murine mast cells. Furthermore, fluvastatin’s suppression is shown in vitro and ex
vivo. Interestingly, fluvastatin’s suppressive capabilities did not extend to IL-10,
widely known as an anti-inflammatory cytokine (42-44).
This study also demonstrates that fluvastatin effects on IgE-induced
cytokine production on primary murine mast cells were reversed with MVA
pretreatment, confirming targeted specificity to the mevalonate pathway. These
data support the findings that suppressed degranulation mediated by fluvastatin
was also rescued by MVA in RBL-2H3 cells (26). As previously stated, MVA
inhibition by statins suppresses the generation of prenylated proteins. Prenylation
is a posttranslational modification, with covalent binding of isoprenoid lipids to
conserved cysteine residues near the C terminus of target proteins (45, 46).
These include the Ras superfamily of small GTP binding proteins, such as Ras,
Rho and Rac.
Prenylated proteins can be further divided into farnesylated proteins and
geranylgeranylated proteins. Since farnesylated and geranylgeranylated proteins
play a critical role In maintaining cell function (47), we investigated the effect of
geranylgeranylation and farnesylation by using GGTI and FPTIII respectively.
Here, we show that GGTI pretreatment significantly inhibited cytokine production
and mimicked the action of fluvastatin, whereas FPTIII only slightly suppressed
IL-6 production. These data suggest that fluvastatin’s ability to suppress IgEinduced cytokine production might be mediated by geranylgeranylation as
opposed to farnesylation. Farnesylation might be more important for the
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arachidonic acid pathway in mast cells (26, 48) (49). It has been reported that
dolichol and cholesterol, which are also synthesized from the mevalonate
pathway, did not restore inhibition of degranulation in RBL-2H3 cells (37) and
were not tested here.
To further corroborate the involvement of geranylgeranylation for IgE
induced cytokine production, we attempted to reverse fluvastatin suppression
with exogenous GGPP and FPP to restore geranylgeranylation and farnesylation,
respectively. We found that GGPP partially rescued cytokine production,
whereas FPP has no significant effect. These data further support the theory that
fluvastatin blockade of geranylgeranylation, more so than farnesylation,
suppresses IgE-induced cytokine production. The importance of upstream lipids
such as isoprenoids was further supported by studies using the squalene
synthase inhibitor zaragozic acid A (ZA) that blocks the formation of squalene
from transfarnesyl pyrophosphate (50). ZA pretreatment did not alter IgE-induced
cytokine production despite suppressing cholesterol synthesis, as measured my
mass spectrometry. These latter results suggest that fluvastatin effects are not
due to large scale changes in cholesterol-containing lipid rafts. Taken together,
these data argue that geranylgeranylation has the largest effect on IgE-mediated
cytokine production, and suggest this pathway as a potential target for controlling
the mast cell response.
Allergic asthma is characterized by reversible obstruction of airway hyper
responsiveness, infiltration of inflammatory immune cells into the lungs, coupled
with Th2-mediated cytokines. The mechanism has yet to be fully elucidated, but
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the involvement of inflammatory and structural cells are critical. Current therapies
can be improved upon, especially for patients who respond poorly to traditional
treatments. These include those who remain symptomatic despite high dose
corticosteroid treatment, and account for approximately 10% of asthmatics (51).
Given the time, expense, and risks associated with new drug developments,
exploring previously-approved drugs for alternative disease states may prove to
be beneficial. In the case of asthma, statins are a prime candidate.
There are studies to support statin use in asthma and allergic disease.
Peripheral blood mononuclear cell (PBMC) proliferation and inflammatory
responses were suppressed by fluvastatin in patients with allergic asthma (52).
Furthermore, Atorvastatin in conjunction to inhaled corticosteroids improved lung
function and airway inflammation in atopic asthmatics (53). These and other
studies have led to the conclusion and statins are beneficial for asthma
management (54). Cellular and molecular mechanisms supporting these clinical
benefits are forthcoming from human and animal studies. Statins may suppress T
cell activation by decreasing MHC II expression on monocytes induced by IFN-γ
(55). T cell activation, proliferation, and migration are also suppressed by statin
treatment (52). This includes Th2 lymphocytes, which play a key role in the
initiation and prolongation of airway inflammation. In addition to their effects on
immune cells, statins have been shown to suppress bronchial wall remodeling
(56).
Among the statins, Simvastatin has been studied in some detail for its
suppressive effects. It has anti-inflammatory capabilities in the murine model of
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allergic asthma (57). This is in partly due to suppression of T lymphocytes and T
cell-produced IL-4 and IL-5 (58). More recently, Kim et al showed that
simvastatin reduced ovalbumin- specific IgE level, number and total of
macrophages, neutrophils and eosinophils into bronchoalveolar lavage fluid (59)
in a mast cell-independent model.

Moreover, Simvastatin also reduced

thioglycolate-induced peritoneal inflammation (60) in which the predominate
infiltrate is neutrophils. This suggests that statins might be beneficial in “nonallergic” asthma, which Is associated with strong Th17 responses and
neutrophilic infiltration (61-63).
Taken together, many studies have investigated immune modulating cells
and the effect statins have on allergic lung function. However, these in vivo
studies have overlooked mast cells, and its fundamental role in allergic asthma
and anaphylaxis. In the airways of asthmatics, mast cells are not only present
(64-66), but fundamental for initiating and maintaining allergic inflammation by
interactions with resident and infiltrating cells in the airway.
As many treatments have shown, targeting and suppressing specific
aspects of mast cell function is beneficial to allergic disease. Using the mast celldependent passive systemic anaphylaxis

(PSA) model, we assessed the

functional validity of our in vitro data. Anaphylaxis is a life threatening acute
systemic reaction caused largely by IgE-mediated release of mediators from
mast cells and basophils to allergen triggers, such as venom, food and
medication (67). Estimated occurrences of anaphylaxis vary greatly, with the
majority of studies agreeing that its prevalence is increasing (68-74). Estimates
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predict a frequency of approximately 50 to 2000 episodes per 100,000 people
(67). Anaphylaxis can also be IgE-independent, caused by agents such as serum
complement activation or direct mast cell degranulation. These IgE-independent
pathways are often directed by non-immunological factors such as exercise, cold
air, or medications such as vancomycin or opioids, and are not fully understood
(69, 75). Regardlesss of the activating pathway, mast cells and to a lesser extent,
basophils are central effector cells in anaphylaxis. Degranulation and the
immediate release of preformed mediators such as histamine, leukotrienes, and
platelet activating factor (PAF) occur between 5 and 30 minutes after cell
activation (76). This gives rise to the hypersensitivity response (69). The delayed
response arises 2-6 hours after initiation and involves the production of cytokines
and chemokines (77).
This study demonstrates that pretreatment with fluvastatin prior to
induction of IgE-mediated PSA dramatically reduced the severity of anaphylaxis
in C57BL/6 mice. These data clearly show the importance of mast cells as a
target and fluvastatin as a therapy for allergic disease. To rule out fluvastatin
primarily provoking a response on the vasculature, we pretreated mice with
fluvastatin and then bypassed the mast cell response by injecting histamine i.p.
Our results showed no significant drop in core body temperature. These data
demonstrate that the dramatic suppression of anaphylaxis is a result of
fluvastatin acting on the mast cells and not the vasculature. Strikingly, mice of the
Th2-prone 129/SvImJ background demonstrated no alteration in anaphylaxis
following pretreatment with fluvastatin. These in vivo data support our in vitro
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findings that 129/SvImJ mast cells are resistant to fluvastatin-mediated
suppression. We postulate that genetic variation could be the cause of these
altered responses in inbred mice.

In addition to the classical anaphylactic pathway, numerous studies have
shown that anaphylactic responses can occur in mice deficient in mast cells (78),
IgE (79) or FcεRIα

chain {Dombrowicz:1997wy}. These data provide an

argument for an alternative pathway, whereby IgG1- dependent activation of the
FcγRIII receptor is required (73). Studies show that although mast cells are
involved, the major cells involved in this pathway are basophils, macrophages
and neutrophils (80). This is a mechanism that can be explored in future work.

Down stream of the IgE receptor, Fyn and Lyn are recruited and activated.
Lyn acts both as a positive and negative regulator, the predominant phenotype
being a negative regulator, as seen in Lyn Knockout mice that demonstrate
increased PSA (81, 82). Our data suggest that statins might be useful in
inflammatory disorders not typically thought of as mast cell-driven, such as lupus.

Along with Fyn down regulation, we further show fluvastatin suppressed
Erk phosphorylation in C57BL/6 but not 129/SvImJ BMMC’s. Additionally, Stat5
phosphorylation was suppressed on C57BL/6 but not 129/SvImJ BMMC. We
previously found that Fyn and Stat5 physically interact, and that Stat5 is crucial
for mast cell function and survival	
  (33, 83, 84). Given the importance of Fyn and
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Stat5 for IgE-mediated cytokine release, suppressing this pathway could explain
the reduced cytokine secretion. Additionally, the Ras–MAPK cascade is
important for differentiation and survival. reduced activation of Stat5 and ERK
could partially explain the increased cell death observed among C57BL/6 mast
cells treated with fluvastatin for prolonged periods.

Variable responses to fluvastatin among C57BL/6 and 129/SvImJ mast
cells are consistent with previous studies from our group. Previously, we
demonstrated that mast cell precursors from the Th2-prone 129/SvImJ
background are resistant to IL-10 (85), and BMMC are resistant to the TGF-βImediated suppression (35). Additionally, 129/SvImJ mice display increased
circulating levels of IgE and an increase in FcεRI expression (86). Therefore we
were intrigued by the lack of fluvastatin effects on 129/SvImJ mice.	
   We further
found that the commonly used Th2-prone Balb/c strain also demonstrated
fluvastatin resistance when assessing IgE-mediated mast cell activation. A
simple conclusion would be that genetic variations predisposing to strong Th1 or
Th2 development show linkage to genetic effects yielding drug resistance.
However, it is important to note that while the C57BL/6 mice are Th1 prone and
129/SvImJ are Th2 prone, this is not their only variation. Moreover, fluvastatin
responses are not simply a Th1-prone versus a Th2-prone phenomenon. Mast
cells from Th2-prone A/J mice did not show complete fluvastatin resistance in
vitro and ex vivo. These observations prompted a deeper investigation into the
mechanisms explaining this pharmacogenomic effect.
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There is a wide variation in inter-individual responses to statin therapy,
and many have hypothesized that genetic differences may contribute to this
variation (87). Clinical data for pharmacogenetic interactions with statins have
largely focused on polymorphisms in the cytochrome P450 enzyme, which
assists in statin export; the lipid metabolism genes apolipoprotein E and B
(APOE,APOB), which control cholesterol transport across the plasma membrane;
and cloesteryl ester transfer protein (CETP) and the LDL receptor (LDLR) which
regulate LDL/VLD protein binding (88-90). CYP2C9 is the primary pathway for
fluvastatin metabolism (91). It might be that functional variants of the CYP2C9
gene are genetic determinants for the lipid response to fluvastatin therapy.
However, this hypothesis while important for in vivo study, would not explain our
in vitro findings.
In addition to these plausible mechanisms yielding statin resistance, there
could be pharmocodynamic gene-drug interactions involving gene products
expressed as receptors after the drug enters circulation (92). A third possibility is
polymorphisms in genes that are in the causal pathway of disease and are
subsequently able to modify the effects of drugs (93). For example, in one study,
a subgroup of coronary heart disease patients did not respond to simvastatin
treatment. This study demonstrated that patients with high baseline synthesis of
cholesterol showed simvastatin responsiveness, whereas those with low
cholesterol synthesis were resistant (94).
Our data show that cholesterol levels are not significantly different
between C57BL/6 and 129/SvImJ BMMC. While, 129/SvImJ BMMC are resistant
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to fluvastatin, they are suppressed by GGTI. We therefore propose that the
variation is above the step of geranyl pyrophosphate in the mevalonic acid
pathway. Thus, it is entirely plausible that the variation is at the level of HMGCoA, being either a polymorphism or alteration in expression between strains.
We therefore sequenced HMGCR (HMG-CoA reductase) from C57BL/6 and
129/SvImJ cDNAs, but found no variations between the strains (data not shown.
We did however demonstrate that 129/SvImJ mast cells have greater than twofold increase in HMGCR following fluvastatin treatment. We therefore propose
that this increase in HMGCR is at least in part responsible for fluvastatin
resistance in 129/SvImJ mice.
The alteration in fluvastatin responsiveness seen in murine mast cells
correlates with variable responsiveness among primary human skin mast cells.
Comparing various donors, we found 18% to 87% suppression by fluvastatin,
when measuring IgE-mediated cytokine secretion. These data demonstrate both
the possible utility of inhibting mast cells reposnses in patients, and the inherent
variability that should be anticipated. Larger numbers of donors are needed to
fully corroborate these findings. Understanding how fluvastatin and statins in
general alter IgE-mediated mast cell signaling and the significance of genetic
background could prove to be important for treating allergic disease.
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Figure 52
The proposed mechanism whereby fluvastatin suppresses the FcεRI
signaling cascade.
Following cross-linking of the FcεRI receptor, the Src family kinases Fyn and Lyn
become activated. Fyn and lyn both actibvate Syk nnd subsequently LAT. Upon
phosphorylation, this scaffold protein serves as a multimolecular signaling
complex allowing for positive signaling down stream of the FcεRI receptor. Lyn
can also act as a negative regulator my recruiting Csk, which inhibits Fyn. This
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figure illustrates the observed signaling molecules inhibited and enhanced by
fluvastatin treatment.
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Part II
The divergent roles of Wnt5a and Leptin on
mast cell function
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Abstract
The prevalence of obesity has reached epidemic proportions in western
countries. Increased levels of adipose tissue are strongly associated with disease
states such as chronic heart disease, atherosclerosis, insulin resistance and type
II diabetes (95). Obesity is also associated with increased risk of inflammatory
conditions such as allergic asthma and allergic rhinitis (96) (97). The obese state
has been described as chronic low-grade inflammation (95, 98). Thus, obesity
and inflammation are inextricably linked. The role of mast cells in inflammatory
disease is unequivocal. Mast cells are instrumental effector cells in IgE-mediated
allergic diseases such as asthma (97, 99) and rhinitis (99) (96) The receptor for
IgE is the high affinity multimeric Fc receptor FcεRI, which when activated
through a IgE-antigen aggregation results in signal transduction. This yields
degranulation and the production of inflammatory and chemotactic mediators.
We hypothesize that the adipokine Wnt5a enhances IgE-mediated mast cell
function and migration. We further hypothesize that the adipokine leptin
suppresses IgE-mediated mast cell cytokine production. These effects may vary
on different genetic backgrounds.
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Chapter 1 - INTRODUCTION:
The prevalence of obesity is on the rise and reaching epidemic
proportions, with 75 million Americans considered obese (95, 100, 101). The
implications of obesity are extensive, altering metabolic processes and immune
responses associated with metabolic syndrome, chronic heart disease,
atherosclerosis, insulin resistance and type II diabetes (95, 101, 102). Recent
studies have explored the relationship between obesity and asthma, indicating
that obesity antedates asthma (102) (103) (104). While the link between obesity
and airway hyper-responsiveness (AHR) is now known, the relationship of
obesity to other inflammatory diseases such as bronchitis, sinusitis, and rhinitis,
the latter of which affects 40% of the American population, is less explored.
Mast cells are instrumental in inflammatory disease. It has been
demonstrated that in obese individuals mast cell numbers are significantly
increased in white adipose tissue (WAT) compared to non-obese (105).
Furthermore, since obesity had recently been described as chronic low-grade
inflammation, it seems logical to explore the relationship between inflammatory
cells and obesity (98, 106). While the role of adipocytes and their adipokines are
well characterized in relation to obesity, their links to allergic inflammation are not
well-understood (95, 107).
The resistance or susceptibility of mice strains to various diseases such as
asthma has been linked to differences in the transcription rates of several
immunologically important molecules such as cytokines, chemokines and their
receptors associated with Th1 and Th2 type immune responses. Using Th1	
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prone C57BL/6 and Th2-prone and 129/sv mice, we show that the adipokine
leptin suppresses mast cells from C57BL/6 mice, but that mast cells from Th2prone mice are resistant to the effects of leptin (108, 109). We propose that like
Th2-prone mice, there are Th2-prone individuals that are predisposed to allergic
disease. And while this predilection is by no means the only contributing factor,
we hypothesize that there is a change in the response of obese Th2-prone
individuals that leads to increased incidence of allergic disease when compared
to Th1-prone individuals. Outlining the role of the mast cell and its response to
adipokines may prove to be crucial for the development of new therapies.

Wnt5a has potential to augment mast cell function
Obesity elicits a dysregulation of adipokines released from adipocytes
and an infiltration of immune cells into adipose tissue. Many adipokines have
been characterized. Our first focus is the effects of Wnt5a on mast cell function.
Wnt proteins are fundamental for basic developmental processes16. Wnt5a has
been shown to signal via Frizzled receptors (Fz) with co-receptors LRP5/6 in the
canonical pathway, and through Fz and Ror2/PTK7/RYK receptors in the noncanonical pathway(110). However, Wnt5a has recently been implicated as
having inflammatory activities, and is elevated in obese individuals (111-113)
(114). Furthermore, the evolutionarily conserved Wnt5a has been implicated as
being a link between the innate and adaptive immune system for microbial
infection(115). It has also been suggested that the inflammatory Wnt5a signaling
pathway is Beta catenin-independent, suggesting that other pathways are
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involved (114). In addition, there is evidence to suggest that Wnt5a and Ror2
activate JNK, contributing to the inflammatory response. For example, these
factors can activate pro-inflammatory cytokine production in endothelial cells in
individuals with Rheumatoid arthritis (114) (116-118). Taken together, these
findings serve as a basis to investigate the inflammatory capabilities of Wnt5a on
mast cell signaling.
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Figure 53
The 3 proposed Wnt signaling pathways.
A) Canonical Wnt/β-catenin pathway. B) non- canonical Wnt/Ca2+ pathway and
the C) non-canonical Wnt/PCP pathway. A) Canonical Wnt β-catenin pathway
regulates

cell

fate

decisions

during

development

of

vertebrates

and

invertebrates. Wnt binds to Frizzled receptors that recruit disheveled which, in
turn results in a down stream signaling cascade that displaces GSK-3β from the
APC/Axin/GSK-3β complex allowing β-catenin to move to the nucleus. In the
absence of Wnt molecules binding frizzled, β-catenin is targeted for proteosomal
degradation. B) In the non-canonical Wnt/Ca2+ pathway, Wnt binds to frizzled
and increases intracellular calcium, which activates CAMKII and transcription
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factors like NFAT and AP-1. C) the non-canonical Wnt/PCP pathway is
characterized by asymmetric distribution of frizzled. This results in cell
polarization. Additionally this pathway activates Rho GTPases such as Rac1,
Cdc42 and RhoA, resulting is cytoskeleton rearrangement and can also activate
JNK.
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The complexities of leptin extend into mast cell homeostasis.
Leptin is primarily produced and synthesized by adipocytes, but its
receptors are found on many cell types, including monocytes and mast cells and leptin effects are felt in many systems (119) (120). Leptin is most commonly
known for its role in energy utilization and storage by regulating energy intake
and expenditure. Leptin levels correlate with adipose tissue mass. Leptin also
regulates metabolic, endocrine, bone metabolism and immune function (120,
121). The leptin receptor knockout (KO) mice db/db, and ob/ob mice lacking
leptin secretion, are not only obese but exhibit endocrine/immune deficiency
(119). Of the 6 leptin isoforms, (Ob-Ra to Ob-Rf) only the long isoform Ob-Rb is
fully functional and capable of downstream signaling through Jak2/Stat3, PI3K
MAPK cascade and SOCS3 (119, 120, 122-124).
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Figure 54
The isoforms of the leptin receptor.
All 6 leptin receptor isoforms share the same ligand binding domain, Cytokine
Receptor Homolog (CRH). With the exception of the OB-Re, which is the
secreted form, all other isoforms are membrane anchored. JAK’s associate with
the conserved Box 1 motif, which is required for JAK2 activation. The OB-Rb
isoform has the longest intracellular domain, which is vital for leptin signaling.
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Although SOCS3 is a feedback inhibitor of leptin and is activated by the
Jak2/Stat3 pathway, structurally, the leptin receptor is similar to the class I
cytokine receptor (gp130) superfamily that include the inflammatory cytokine
receptor IL-6. It also signals much like the IL-6 receptor, and has been
demonstrated to act as a pro inflammatory mediator in macrophages (119, 125).
Furthermore, leptin production is increased in inflammation (126), promoting a
Th1 response. However, it has been shown that the loss of the leptin or its
receptor results in exacerbated airway hyperresponsiveness, suggesting an
inhibitory role for leptin also (127).
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RESULTS:
Wnt5a enhances IgE induced cytokine production in primary BMMC’s.
We initially investigated the adipokines Wnt5a, leptin, adiponectn and
resistin and found wnt5a and leptin to yield the most interesting results. Here, we
show that IgE sensitized BMMC’s pretreated with Wnt5a for 3 show a significant
increase in IL-and TNFα (Figure 55) production on the Th1 prone C57BL/6 mast
cells. Interestingly Wnt5a did not significantly alter IL-10 production (Figure 56)
on C57BL/6 mast cells. To determine the potential of genotype dependence, we
treated BMMC’s from the Th2 prone 129/SvImJ with Wnt5a. Here, we show that
129/SvImJ exhibit an increase in IL-6, TNFα, IL-13 and MCP-1 (Figure 57). We
demonstrate that the effect of Wnt5a on murine mast cell is not genotype
restricted.
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Figure 55
Wnt5a Enhances cytokine production from IgE activated BMMC’s.
C57BL/6 were cultured in IL-3 and SCF, with or without Wnt5a for 3 days.
BMMC’s were then sensitized with IgE over night and then activated with DNPHSA for 16 hours and supernatants were collected as described in the methods
and materials and assessed by standard sandwich ELISA to determine IL-6 and
TNFα concentrations. The results are expressed as the mean ± SEM of 3
independent experiments.
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Figure 56
Wnt5a does not alter IL-10 production from IgE activated mast cells.
C57BL/6 were cultured in IL-3 and SCF, with or without Wnt5a for 3 days.
BMMC’s were then sensitized with IgE over night and then activated with DNPHSA for 16 hours and supernatants were collected as described in the methods
and materials and assessed by standard sandwich ELISA to determine IL-10
concentrations. The results are expressed as the mean ± SEM of 2 independent
experiments.
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Figure 57
Wnt5a Enhances cytokines and chemokine production from IgE activated
mast cells.
129/SvImJ BMMC’s were cultured in IL-3 and SCF, with or without Wnt5a for 3
days. BMMC’s were then sensitized with IgE over night and then activated with
DNP-HSA for 16 hours and supernatants were collected as described in the
methods and materials and assessed by standard sandwich ELISA to determine
A) IL-6, B) TNFα, C) IL-13 D) MCP-1 concentrations. The results are expressed
as the mean ± SEM of 3 independent experiments.
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Wnt5a enhances mast cell migration
Following Wnt5a’s ability to increase IgE mediated pro-inflammatory
cytokines; and given that mast cells migrate to sites of infection, we wanted to
investigate the ability of Wnt5a to alter mast cell migration and mast cell
migration towards antigen. Here, we show that mast cells from C57BL/6 mice
migrate towards Wnt5a (Figure 58 A), and more so in the presence of antigen
(Figure 59 B).
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Figure 58
Wnt5a enhances mast cell migration.
A) C57BL/6 BMMC’s were tested through 8µm transwell membrane for migration
in response to media alone or Wnt5a (100ng/ml). Fold migration is in response to
samples containing media alone. The results are expressed as the mean ± SEM
of 2 independent experiments. B) C57BL/6 BMMC’s were cultures for 3 days IL-3
(10ng/ml) and SCF (10ng/ml) ± Wnt5a (100ng/ml) and sensitized with IgE.
BMMC’s were then tested through 8µm transwell membrane for antigen-induced
migration. Fold migration is in response to samples containing media alone. The
results are expressed as the mean ± SEM of 2 independent experiments.
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Wnt5a enhances IgE induced cytokine production in basophils
We next wanted to see if Wnt5a and leptin altered basophil cytokine
production. Here, we show that Wnt5a increases IL-6 (Figure 59) and TNFα
(Figure 60) production but pretreatment with leptin does not significantly alter
basophil cytokine production.
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Figure 59
Wnt5a increases IgE mediated IL-6 production in basophils.
Bone marrow derived basophils from C57/BL6 mice were cultured for 3 days in
IL-3 (10ng/ml). On day 4 they were treated with ± Wnt5A (25ng/ml) or ± leptin
(250ng/ml) and then cross-linked with IgE (0.5ug/ml) and DNP-HSA antigen (IgE
XL) on day 7. Cytokines levels were measured intracellularly by flow cytometry.
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Figure 60
Wnt5a increases IgE mediated TNFα production in basophils.
Bone marrow derived basophils from C57/BL6 mice were cultured for 3 days in
IL-3 (10ng/ml). On day 4 they were treated with ± Wnt5A (25ng/ml) or ± Leptin
(250ng/ml) and then cross-linked with IgE (0.5ug/ml) and DNP-HSA antigen (IgE
XL) on day 7. Cytokines levels were measured intracellularly by flow cytometry.
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Leptin suppresses IgE induced cytokine production on mast cells
As mentioned previously, leptin plays a role in inflammation and thus we
wanted to assess the ability of leptin to alter mast cell cytokine production whilst
looking at any potential genotype dependence. Interestingly, we show that
BMMC’s pretreated with or without leptin for 3 days that were then IgE sensitized
and activated with antigen actually suppress cytokine production on C57BL/6
mice but on the Th2 prone 129/SvImJ mice we see that BMMC’s are resistant to
the suppressive capabilities of leptin.
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Figure 61
Leptin suppresses IL-6 production from IgE activated BMMC’s on the Th1
prone C57BL/6 background but not the TH2 prone 129/SvImJ BMMC’s.
C57BL/6 and 129/SvImJ IgE sensitized BMMC’s were cultured in IL-3 and SCF
with or without Leptin for 3 days, then sensitized with IgE and then activated with
antigen for 16 hours. Supernatants were collected as described in the methods
and materials. The results are expressed as the mean ± SEM of 3 independent
experiments.
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Figure 62
Leptin suppresses TNFα production from IgE activated BMMC’s on the Th1
prone C57BL/6 background but not the TH2 prone 129/SvImJ BMMC’s.
C57BL/6 and 129/SvImJ IgE sensitized BMMC’s were cultured in IL-3 and SCF
with or without Leptin for 3 days, then sensitized with IgE and then activated with
antigen for 16 hours. Supernatants were collected as described in the methods
and materials. The results are expressed as the mean ± SEM of 3 independent
experiments.
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Figure 63
Leptin suppresses MIP-1 production from IgE activated BMMC’s on the Th1
prone C57BL/6 background but not the Th2 prone 129/SvImJ BMMC’s.
C57BL/6 and 129/SvImJ IgE sensitized BMMC’s were cultured in IL-3 and SCF
with or without Leptin for 3 days, then sensitized with IgE and then activated with
antigen for 16 hours. Supernatants were collected as described in the methods
and materials. The results are expressed as the mean ± SEM of 3 independent
experiments.
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Leptin receptor deficiency exacerbates anaphylaxis, but reduces histamine
release
We next wanted to investigate the effect leptin deficiency has on passive
systemic anaphylaxis, which is dependent apon mast cell IgE mediated
activation. We therefore assessed this response on leptin receptor knockout mice
(db/db mice) and their Wilt type (WT) counterparts. While the difference between
the KO and wild type is small, the KO mice take a significantly longer time to
recover

(Figure

64).

The

db/db

mice

responsiveness to histamine (Figure 65).
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Figure 64
Leptin receptor deficiency worsens anaphylaxis, but reduces histamine
release.
WT (C57BL/6) or Leptin receptor knockout mice (n=4) A) were sensitized with IV
injection of IgE anti-DNP, and then injected with DNP-BSA the following day.
Change in body temperature was measured by rectal probe. B) Mice were
injected with 5mg histamine, i.v. Change in core body temperature was
measured by rectal probe at regular intervals.
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Figure 65
Leptin receptor deficiency reduces histamine release.
WT (C57BL/6) or Leptin receptor knockout mice (n=4) A) were sensitized with IV
injection of IgE anti-DNP, then injected with DNP-BSA the following day. Change
in body temperature was measured by rectal probe. B) Mice were injected with
5mg histamine, IV, and change in temperature was measured.
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DISCUSSION:
The effects of Wnt5a and leptin on mast cells
Recently

it

has

been

shown

that

adipokines

play

a

role

in

immunomodulation, in particular that Wnt5a has inflammatory capabilities (95,
111, 112) and that Wnt5a is implicated as being a link between the adaptive and
innate immune system. Here, we show that Wnt5a significantly enhances the
release of inflammatory mediators from mast cells. Furthermore, these data
suggest that Wnt5a also enhance mast cell migration. Additionally, our
preliminary data show that pretreatment with leptin causes suppression of
cytokine production on the Th1 prone genetic background but not the Th2 prone
129/SvImJ background. Unfortunately, although interesting out data did not
consistently repeat leading us to halt this investigation.
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